Quality of Life and Viral Infections in Adults with Hemophilia* by Holsbach, Denise Rodrigues et al.
InternatIonal archIves of MedIcIne 
sectIon: heMatology
ISSN: 1755-7682
International 
Medical Society 
http://imedicalsociety.org
1
2016
Vol. 9 No. 347
doi: 10.3823/2218
© Under License of Creative Commons Attribution 3.0 License This article is available at: www.intarchmed.com and www.medbrary.com 
Abstract
Objective: To check the occurrence of viral infections resulting from 
treatment with blood products and their impact on quality of life in 
the health of adult patients with hemophilia. 
Method: This is a cross-sectional study with a convenience sample 
conducted with an association of patients. Data collection took place 
in November and December 2015. The evaluation protocol used the 
application of the SF-36 questionnaire and a form to collect demo-
graphic and clinical data. 
Results: The participants were 49 adult patients with hemophilia, 
male, with an average age of 32±8.5 years old. They had a higher 
prevalence of hemophilia A in its severe form. Viral infections were 
more prevalent in those who had hemophilia when hepatitis C was 
the most frequent infection. Viral infections had a negative impact 
on quality of life in the “physical capacity,” “pain,” “general health” 
and “mental health.” The age of the participants who experienced 
viral infections resulting from treatment with blood transfusions were 
significantly higher than the uninfected participants. 
Conclusion: Viral infections resulting from treatment with blood pro-
ducts in hemophiliac patients have repercussions in a lower quality of 
life of patients with hemophilia. The infections were more frequent 
with increasing age, suggesting special attention to older patients.
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Introduction
Hemophilia A and B are hereditary hemorrhagic coagulopathies linked 
to the chromosome X, characterized by a quantitative deficiency of 
clotting factors VIII and IX. Data from the “Profile of inherited coa-
gulopathies in Brazil: 2014” show that the country has 21,066 pa-
tients with inherited coagulopathies, and 9,616 (45.65%) of them 
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are hemophilia A, 1,881 (8.93%) are hemophilia B 
and 9569 (45.42%) are other coagulopathies and 
bleeding disorders [1, 2].
Treatment for hemophilia until the 40s consisted 
of rest, use of compression bandages, immobiliza-
tion, and ice as palliative care in the hemarthroses 
[3]. From the 50s, the use of fresh or frozen plasma 
infusion has started as a source of factor VIII, with 
difficulty to obtain adequate plasma levels without 
risk of circulatory overload in hospitals [4].
In 1964, Judith Pool created the cryoprecipitate 
from a fraction of the plasma removed containing 
large amounts of factor VIII. The product could be 
administered to the patient and reduce mortality 
rates as well as school and work absenteeism at 
the time [5].
The introduction to prophylactic treatment du-
ring the 70s proved its effectiveness as a treatment 
on demand. However, patients who were frequent 
using plasma transfusions or their derivatives were 
infected by viruses such as HIV and hepatitis C du-
ring the 80s and 90s [6, 7]. However, from 1993 the 
donor would undergo a screening when identifying 
items such as infectious diseases to be a donor [8].
In the early 90s, the scientific community star-
ted researching on DNA technologies to provide 
treatment with recombinant factor VIII and IX and 
the development of viral inactivation methods in 
blood products [6].
The replacement of factors VIII and IX of coagula-
tion synthesized by recombinant technology do not 
give the risk of infection by the hepatitis B and C 
or HIV viruses [1]. With this technology, there was 
a safer therapy, and the possibilities for prevention 
and treatment of the consequences of hemophilia 
were increased.
Hemophilia can interfere with the individual´s life 
due to its complexity, effects and associated comor-
bidities. Due to the chronic nature of the disease, it 
can lead to physical and/or psychological changes 
of the patients. When considering the aspects men-
tioned, the investigation of the quality of life (QOL) 
in the perception of the individual with hemophilia 
is necessary. The quality of life is understood as 
the patients´ perception of their well-being in seve-
ral areas, including the physical, emotional, mental, 
social and behavioral [10].
In this context, this study aimed to check the oc-
currence of viral infections resulting from treatment 
with blood products and their impact on quality 
of life related to the health of adult patients with 
hemophilia.
Method
This is a cross-sectional study with a quantitative ap-
proach, conducted with patients with a hemophilia 
diagnosis, linked to the Association of volunteers, 
researchers, and patients with coagulopathy (AJU-
DE-C) located in Brasília/DF, the capital of Brazil.
The sampling was by convenience for the eligi-
bility criteria and methods of selection of partici-
pants. The population consisted of all members of 
the studied patients association. The final sample 
included 49 hemophilia patients, male, 18 years old 
who agreed to participate voluntarily and signed the 
Informed Consent Form (TCLE). Those with cogni-
tive impairment and those not present in the As-
sociation during data collection were not included.
Data collection took place between November 
and December 2015, with meetings and events on 
dates previously reported by the Association. An 
individual invitation was made to patients with the 
approach of the research objectives and after the 
volunteers accepted to participate the TCLE was 
presented for its consideration and signature. After 
including the subjects, the instruments adopted to 
collect data of the study were administered in an 
individual and reserved way.
This study had two instruments for data collec-
tion; the first instrument was the “Medical Outco-
mes Study 36 - Item Short-Form Health Survey” (SF 
- 36) and the second instrument was an Evaluation 
Form.
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The instrument “Medical Outcomes Study 36 - 
Item Short-Form Health Survey” (SF-36) is a generic 
questionnaire to assess the quality of life. It was 
translated into Portuguese (Brazilian version) and 
validated to use it in Brazilian Portuguese. [11]
The Evaluation Form was developed specifically 
for this study, and it has items to design the socio-
demographic characteristics such as age, race/skin 
color, educational level and marital status, as well as 
items for the clinical characterization with topics on 
the type of hemophilia, its clinical severity and viral 
infections resulting from the treatment.
The descriptive results statistically analyzed were 
presented as average and standard deviations, cate-
gorical results for absolute frequency and/or relative 
measurements. The comparison between the types 
of hemophilia and the variables “clinical severity,” 
“viral infection by the use of blood products” and 
“type of viral infection” was performed by the chi-
square test.
The comparison between hemophiliacs who had 
viral infections from treatment with blood products 
and those that did not about the scores in each 
domain of the SF-36 and relation to age of the pa-
tients was performed using the Mann-Whitney test. 
Statistical analysis was performed using SPSS, ver-
sion 22.0. The study adopted 5% significance level.
The research study protocol was previously ap-
proved in its ethical, and methodological aspects 
by the Ethics Committee in Research with Human 
Beings of the Federal University of Mato Grosso do 
Sul (UFMS), in the opinion Nº 1,300,316 and CAAE 
Nº 46914215.6.0000.0021.
Results
The study participants were 49 adult hemophilia pa-
tients and male. The average age and the standard 
deviation was 32±8.61 years old, respectively. The 
most prevalent age group was between 20 to 29 
years old (46.9%). There was a higher prevalence 
of brown ethnicity hemophiliacs (49%) and single 
marital status (61.2%) (Table 1).
Table 2 shows the results for the association bet-
ween the type of hemophilia and the variables “cli-
nical severity,” “presence of viral infections by blood 
transfusion” and “type of viral infection.” There was 
Table 1.  Socio-demographic characteristics of the 
sample of patients with hemophilia. Brasí-
lia/DF, 2016 (n=49.
Variable n % Average±SD*
Age (years old
20-29 23 46.9
32.3±8.61
30-39 17 34.7
40-49 06 12.2
50-59 03 6.1
Ethnicity
Brown 24 49.0
White 19 38.8
Black 06 12.2
Marital Status
Single 30 61.2
Married 19 38.8
*: Standard deviation
Table 2.  Clinical severity and viral infection by the 
use of blood products of hemophilia pa-
tients. Brasília/DF, 2016 (n=49).
Variable
Hemophilia A Hemophilia B
P1
n % n %
Clinical severity
Mild 01 ( 2.6) 01 ( 9.1)
0.286Moderate 06 ( 15.4) 03 ( 36.4)
Severe 32 ( 82.1) 06 ( 54.5)
Viral infection by the use of blood products
Yes 23 ( 59.0) 04 ( 40.0)
0.282
No 16 ( 41.0) 06 ( 60.0)
Type of viral 
infection
(n=23) (n=4)
HIV2 01 ( 4.3) 00 ( 0.0)
0.738
VHC3 18 ( 78.3) 04 ( 100.0)
VHC e HIV 02 ( 8.7) 00 ( 0.0)
VHC e 
VHB4
02 ( 8.7) 00 ( 0.0)
1: Chi-square test, 2: Human immunodeficiency virus, 
3: Hepatitis C Virus, 4: Hepatitis B Virus.
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no statistically significant association between the 
type of hemophilia and other variables. Hemophi-
lia A was classified as severe, and it was the most 
prevalent in this study (82.1%). Regarding the viral 
infections by blood transfusion, 23 cases (58.97%) 
occurred in patients with hemophilia A and four 
cases (40%) in patients with hemophilia B.
Table 3 shows the analysis of the variables related 
to the quality of life of affected patients with hemo-
philia by viral infections related to the use of blood 
products contaminated according to each SF-36 do-
main. There were statistically significant differences 
in the domains of “physical capacity,” “pain,” “ge-
neral health” and “mental health,” since in these 
areas the scores in patients with viral infections by 
blood products was lower than in those without 
this type of infection.
A relevant fact was the age of the participants 
with viral infection by blood products (37.55±8.10 
years old), significantly higher than the partici-
pants who did not have it (p <0.001), as shown 
in Figure 1.
Discussion
The age of the participants in this study ranged 
from 21-54 years old, average of 32 years old, so 
there was no presence of elderly in the sample. 
Garbin and colleagues [12] conducted research with 
hemophiliac adults and they found an average age 
of 34.36±11.9 years old (between 18 and 66 years 
old) and prevalence of individuals aged 21-29 years 
old. The lower portion of hemophiliac elderly of that 
study was probably due to the high mortality, espe-
cially due to HIV infection when using contaminated 
blood transfusions occurred in the 80s.
In this work, most subjects were reported as 
brown (49%), followed by whites (38.8%) and 
blacks (12.2%). Zago, Hawk, and Pasquini reported 
that the prevalence of hemophilia A and B show no 
racial differences. However, rare cases are present 
in Chinese and African [13].
In the center-west region of Brazil, there is a pre-
dominance of brown subjects (50.6%) [14]. How-
ever, research conducted by Almeida and colleagues 
[15] with 34 hemophiliac participants from a public 
Table 3.  Analysis of the quality of life according to 
the scores of the SF-36 among patients 
with hemophilia who had viral infections 
by blood transfusion and those without 
infection Brasília/DF, 2016 (n=49).
Domains of SF-
36
Viral infection by the use of 
blood transfusion 
p2
Yes No
Average±SD1 Average±SD1
Physical capacity 52.78±24.54 72.72±23.18 0.009
Physical aspects 57.40±44.29 75.00±37.79 0.116
Pain 52.93±21.20 67.50±19.77 0.038
General health 54.30±23.13 71.45±17.20 0.005
Vitality 60.74±26.15 72.72±13.42 0.302
Social aspects 73.61±29.28 87.50±14.94 0.187
Emotional 
aspects
60.48±44.37 83.33±35.26 0.066
Mental health 68.44±22.08 79.09±11.10 0.048
1: Standard deviation, 2: Mann-Whitney test.
Figure 1:  Age analysis of participants with viral 
infection by blood transfusion and tho-
se who did not. The column represents 
the average, and the bar is the standard 
deviation of the average.
*: Statistically significant difference (p <0.001) Mann-Whitney test.
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reference center of Brasília/DF found a predomi-
nance of Caucasians (63.7%), followed by brown 
(33.3%) and black (3%).
Regarding marital status, the research showed a 
predominance of hemophiliac singles (61%). These 
findings corroborate those found by Garbin et al. 
[12], where 60% of hemophiliac adults lived alone 
(single or divorced), as well as research of Nunes et 
al. [16] with 78.3% of the sample and of the study 
Almeida et al. [15], with 69.7% of participants.
These results can be explained by the difficulty 
of coping with the disease and its social repercus-
sions, the presence of concomitant viral infections 
due to the use of contaminated blood products, 
physical limitations and therefore difficult to work 
[12]. Caio et al. [17] mentioned that the establish-
ment of a family is an important point of support 
for hemophiliac adults. However, the lack of access 
to a satisfactory regular employment is a major fac-
tor of social inadequacy. Also, 65% of hemophiliacs 
prefer not to have children if the hypothetical risk of 
generating a hemophiliac child increases.
The results of this study demonstrate a high-
er prevalence of hemophilia in the participants 
(82.5%) compared with hemophilia B (17.5%). Thus, 
a Brazilian study by Ferreira et al. [18] included 39 
hemophilia participants, of which 33 were hemo-
philiacs A (84.6%). Other research conducted by 
Adams and colleagues [15] found a prevalence of 
hemophilia A in 91% of the sample. Hemophilia A 
is considered to be more prevalent than B with a 
prevalence of 1/20,000 and 1/10,000 individuals, 
while for hemophilia B is 1/30,000 to 1/50,000 
individuals [13].
The results of this study in the clinical severity of 
hemophilia classification pointed to the prevalence 
of a severe disease (77.6%), followed by moder-
ate (18.4%) and light (4.1%). Almeida et al. (2011) 
corroborated these findings and reported that the 
clinical classification of the participants was severe 
in 60.6%, moderate in 33.4% and mild in 6%. Se-
vere hemophilia is present in approximately 50% of 
patients, 10% are classified as moderate, and 40% 
with mild categorization [13].
There were 27 participants of the 49 subjects in 
this study having viral infections, when there was 
a predominance of Hepatitis C. Similar results were 
presented by Garbin et al. [12], where 20 (66.6%) 
participants reported infectious comorbidities, with 
a prevalence of hepatitis C infection (40%). Carmo 
et al. [19] reported that hemophiliacs were at high 
risk of hepatitis C infection before to the viral in-
activation treatments. They showed that hepatitis 
C infection is a major problem in the Brazilian he-
mophiliacs, associated with age, co-infection with 
hepatitis B and inhibitor development of coagula-
tion factor.
When comparing hemophiliacs who had a vi-
ral infection due to the use of blood products 
and those who showed no differences the qual-
ity of life (QOL) statistics in the domain scores 
“physical capacity”, “pain”, “general health” and 
“mental health”. Ferreira et al. [18] found statisti-
cally significant differences when comparing he-
mophiliacs with HCV infection (p=0.017) and HIV 
(p=0.025) compared to those not infected and 
reported that QOL in hemophiliac adult patients, 
measured by the use of HAEM-A-QoL instrument 
was diminished by the presence of hemophilic ar-
thropathy and infectious diseases transmitted by 
blood products.
Mauser-Bunschoten, Fransen van de Putte and 
Schutgens [20] agree and indicate that the hemo-
philiac adults and the elderly have different prob-
lems compared to the new generation. They show 
premature hemophilic arthropathy due to lack of 
treatment as well as viral infections with HCV and/
or HIV, which can lead to physical and psychologi-
cal implications. The psychological aspects can be 
triggered mainly by job loss, early retirement, health 
decline and change in family dynamics, with de-
creasing autonomy.
Similar results of this study were presented by 
Posthouwer and colleagues [21], where hemophili-
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acs infected with HCV had low QOL compared 
to uninfected hemophiliacs, with lower scores for 
“general health” and “vitality.”
HIV infection in hemophiliac adults has been 
shown to cause significant deterioration in QOL 
observed by the decrease in scores on “mental 
health” in the SF-36 [22] instrument. However, 
different results were found for Miners and col-
leagues [23] when there was no evidence that HIV 
infection has affected the QOL of the evaluated 
hemophiliacs.
A study [15] found decreased in all scores of the 
SF-36 questionnaire and HAEM-A-QOL compared 
hemophiliacs with infections with hepatitis B and 
C with those without infection. The largest differ-
ences were observed in the functional capacity, 
general health, vitality, functional capacity, bleed-
ing and emotional impact (p <0.05). Barr et al. [24] 
reported that hepatitis and HIV confer additional 
morbidity, especially on items such as “mobility” 
and “pain,” generating statistical differences.
In this study, the age of the hemophiliac par-
ticipants infected with virus resulting from blood 
transfusions treatment was significantly higher than 
those who did not show this type of infection, 
when all individuals born from 1994 were free of 
viral infection.
Only from November 1993 through the Decree 
1376 of the Ministry of Health of Brazil criteria for 
selection and screening of blood donors were esta-
blished, as well as laboratory and virus techniques 
in blood products [8]. Viral infections have declined 
due to the careful screening blood donors as well as 
individual testing for antiviral antibodies, antigens, 
and nucleic acids. These techniques were further 
supplemented by non-specific viral reduction by 
physical inactivation of pathogens (heat) and che-
mical inactivation (solvent-detergent) [25].
In the 70s and 80s, transfusions with plasma pool 
led to the contamination of many individuals with 
HIV and hepatitis C, triggering the development of 
free blood products for viral contamination, and 
they combined improvement in the screening and 
selection of blood donors with effective virus tech-
niques and the use of recombinant technology for 
genetic engineering [26].
Conclusion
The age of the participants who experienced viral 
infections resulting from treatment with contamina-
ted blood products is significantly higher than the 
uninfected participants. This may be associated with 
the chronological period without selection criteria 
for blood donors and viral inactivation techniques.
It was found that viral infections, particularly 
hepatitis C, are factors that diminish the quality of 
life of hemophiliac adults, especially in the items 
“physical capacity,” “pain,” “general health” and 
“mental health.”
Such infections arose from the treatment with 
blood products contaminated before the implemen-
tation of stringent selection criteria and screening 
for donors associated with the use of virus tech-
niques. The use of recombinant technology, not de-
rived from human or animal plasma, brought safely 
to patients in need of treatment for replacement of 
the deficient coagulation factor on a regular basis.
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